TIVC vs DBVT vs ALKS vs ELMD

For growth investors, Electromed, Inc.

(ELMD) is the stronger pick with 17. 0% revenue growth year-over-year, versus -33. 7% for Tivic Health Systems, Inc. (TIVC). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Electromed, Inc. at 31. 2x.

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +178. 1%, compared to -100. 0% for Tivic Health Systems, Inc. (TIVC). Over 10 years, the gap is even starker: ELMD returned +482. 6% versus TIVC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Electromed, Inc.

(ELMD) is the lower-risk stock at 1. 03β versus Tivic Health Systems, Inc. 's 2. 19β — meaning TIVC is approximately 113% more volatile than ELMD relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Electromed, Inc.

(ELMD) is pulling ahead at 17. 0% versus -33. 7% for Tivic Health Systems, Inc. (TIVC). On earnings-per-share growth, the picture is similar: Tivic Health Systems, Inc. grew EPS 88. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ELMD leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -725. 0% for Tivic Health Systems, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -725. 8% for TIVC. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Electromed, Inc.

(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +482. 6% 10Y return). Tivic Health Systems, Inc. (TIVC) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +482. 6%, TIVC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TIVC is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ELMD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.